Search

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

741 questions · 808 findings · 27 reviews · Oral medicine and oral cancer · related questions CL0289

No studies found 95 · 11.8%GRADE not reported 498 · 61.6%Very low 134 · 16.6%Low 53 · 6.6%Moderate 27 · 3.3%High 1 · 0.1%

NSAIDs (ketorolac oral rinse; systemic celecoxib) vs placebo or no treatment

Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia

The review found no eligible studies for this question.

1 finding from 1 review

Benzodiazepines (systemic clonazepam 0.5 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (systemic clonazepam 0.5 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Systemic beta carotene or carotenoids (incl. lycopene) vs placebo or no treatment

Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia

Systemic beta carotene or carotenoids (incl. lycopene) may leads to lower improvement of histological features (not improved) compared with placebo or no treatment (low certainty).

1 finding from 1 review

Bowman-Birk inhibitor vs placebo or no treatment

Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • SoF 6, Histological changes: 'Not measured'. Effects text: data on histological changes from Armstrong 2013 were not available for analysis, but study authors reported no statistically significant differences in…
    1 study
    GRADE not reported

Physical barriers (tongue protector) vs placebo

Change in QoL - anxiety (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether physical barriers (tongue protector) changes change in QoL - anxiety (surrogate marker) compared with placebo (very low certainty).

1 finding from 1 review

Cholinergics (bethanechol 15 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether cholinergics (bethanechol 15 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Psychological therapies (cognitive therapy) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether psychological therapies (cognitive therapy) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Topical treatments (capsaicin oral rinse) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
2 findings from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · capsaicin oral rinse
    Capsaicin oral rinse (Marino 2010; Silvestre 2012) contributes to the topical treatments short-term symptom-relief comparison (insufficient/contradictory). Silvestre 2012 data not presented due to 23% first-phase…
    1 study
    GRADE not reported
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    long-term (>3 to 6 months) · capsaicin oral rinse
    MD -2.60 [-5.11, -0.09]
    1 study · 18 participants
    Very low

Systemic beta carotene or carotenoids (incl. lycopene) vs placebo or no treatment

Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia

It is very uncertain whether systemic beta carotene or carotenoids (incl. lycopene) changes oral cancer development compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Amisulpride (antipsychotic, 50 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months)
    Bogetto 1999 (amisulpride) included in the antidepressants/antipsychotics comparison but data not presented due to excessive attrition (19/24; 79%) in the placebo arm.
    1 study
    GRADE not reported

Gabapentin vs placebo

Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

The review found no eligible studies for this question.

1 finding from 1 review

Bethanechol vs placebo

Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

The review found no eligible studies for this question.

1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines (systemic clordemetildiazepam 1 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · clordemetildiazepam
    Bogetto 1999 (clordemetildiazepam) included in the benzodiazepine comparison but data not presented (79% placebo-arm attrition).
    1 study
    GRADE not reported

Physical barriers (tongue protector + reinforced self-control instruction) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether physical barriers (tongue protector + reinforced self-control… changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Amitriptyline vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review

Topical treatments (topical urea 10%) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · topical urea 10%
    Topical urea 10% (Alvarenga da Silva 2014) contributes to the topical treatments short-term symptom-relief comparison (insufficient/contradictory); no separate estimate reported.
    1 study · 38 participants
    GRADE not reported